Follow up of patients with chronic granulomatous disease diagnosed since 1990

Citation
Cm. Cale et al., Follow up of patients with chronic granulomatous disease diagnosed since 1990, CLIN EXP IM, 120(2), 2000, pp. 351-355
Citations number
24
Categorie Soggetti
Immunology
Journal title
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
ISSN journal
00099104 → ACNP
Volume
120
Issue
2
Year of publication
2000
Pages
351 - 355
Database
ISI
SICI code
0009-9104(200005)120:2<351:FUOPWC>2.0.ZU;2-J
Abstract
Outcomes for children with chronic granulomatous disease (CGD) have histori cally been poor, but significant improvements have occurred with the use of effective antibacterial prophylaxis. The present study aimed to document t he clinical course of a cohort of children diagnosed with CGD since 1990 in a single centre. Twenty-one patients were identified, with a median age at last assessment of 4 years and 5 months. A third of these children were di agnosed in infancy because of a positive family history. Of the remaining, there was a median delay between the onset of symptoms and diagnosis of 13 months. No invasive or fungal infections were documented after diagnosis, n or were there any deaths in this cohort. A variety of non-infectious compli cations were noted, which responded well to steroids. As a group, these chi ldren were thriving and weight and height distributions fell within the pop ulation norm. All patients were receiving antibacterial prophylaxis, 90% wi th co-trimoxazole, and all but one patient were receiving a prophylactic an ti-fungal agent (itraconazole). Both drugs were well tolerated. In conclusi on, this cohort of patients, diagnosed in the last decade, tolerated antiba cterial and anti-fungal prophylaxis well and on this regimen have a signifi cantly decreased incidence of infection when compared with historical cohor ts. Careful follow up of patients who have had aggressive antibacterial and anti-fungal prophylaxis should continue. The data reported on this cohort of patients should inform the debate about the use of more aggressive treat ments, such as bone marrow transplantation, in this disease.